Our findings indicate that targeting of certain EVs from CD8+ T cells to mesenchymal tumour stromal cells is useful for future treatment of patients with metastatic refractory tumours, including pancreatic cancer. The gene discussed is CD8A; the disease is pancreatic neoplasm.